AIDS Alert Archives – July 1, 2007
July 1, 2007
View Issues
-
Black churches increasingly play role in HIV prevention, but problems remain
The CDC made broader community mobilization a major goal in the new initiative to heighten the fight against HIV in the African American community. -
Researchers adapt HIV prevention program from MSM to African American cohort
One of the challenges facing HIV/AIDS clinics attempting to implement prevention programs for African Americans is that there are few evidence-based programs directed toward this population available and approved by the Centers for Disease Control and Prevention (CDC) of Atlanta, GA. -
Prevention intervention focuses on African American boys and their fathers
The 8-year-old REAL (responsible, empowered, aware, living) study includes an intervention that focuses on fathers and their roles in educating and guiding adolescent boys to safe decisions. -
FDA Notifications
The Food and Drug Administration (FDA) granted approval, on May 23, 2007, to a generic formulation of zidovudine capsules, 100 mg, manufactured by Cipla Limited, of Mumbai, India. -
Leprosy revealed with HIV treatment
HIV/AIDS specialists in britain and the U.S. caring for HIV+ persons from developing countries are reporting a new phenomenon - exacerbations of previously unrecognized leprosy in HIV+ persons receiving highly active antiretroviral therapy (HAART). As patients initiate HAART, and with improvement in their immune systems, their leprosy appears to "wake up." -
HIV+ patients still need PCP prophylaxis
Prophylaxis against pcp remains the single most cost-effective intervention in HIV+ patients at risk. But treatment has, in some ways, become a moving target in some patients, as their CD4 count rises and falls with newer HIV therapies, medication side effects, and variable compliance. -
Condoms prevent HPV in sexually naïve women
The debate surrounding the relative merits of abstinence and fidelity vs. condom use (as if the two were mutually exclusive) remains a hotly contested issue, at least in the United States, where it has even spilled over into U.S. international family planning policy. -
IL-2 in HIV Infection: Raises CD4+ Cells, But at What Cost?
Actg 328 was a multicenter trial that studied HIV-1 infected adults without active AIDS-defining illnesses and with CD4+ lymphocyte counts between 50 and 350/uL. Patients were protease inhibitor (PI) and IL-2 naïve but may have received prior nucleoside analogue therapy. -
AIDS Alert International: Microbicide Research Will Prevail Despite Most Recent Setback, Experts Say
Microbicide research suffered a setback earlier this year when a phase III clinical trial studying cellulose sulfate to block HIV infection was stopped prematurely because there appeared to be a higher rate of HIV infections among the study group than the control group. -
AIDS Alert International: Study recommends monthly HIV tests for women in ART microbicide trials
The latest microbicide clinical trials will use antiretroviral therapy (ART), which holds both promise and more challenges for investigators. -
AIDS Alert International: Report discusses ART access in low and middle income nations
More than two million people living with HIV/AIDS in low and middle income countries now have access to antiretroviral therapy (ART), according to a recent report.